Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Adela Joanta-Gomez"'
Autor:
Carlen Yuen, Peter Pan, Damian Teasley, Michael Miller, Yu Sun, Peter Canoll, Adela Joanta-Gomez, Alicia Bargo, Fabio Iwamoto
Publikováno v:
Neuro-Oncology. 24:vii157-vii157
BACKGROUND The new WHO 2021 classification included CDKN2A/B loss and TERT mutation as new criteria for Grade 3 meningiomas, but excluded H3K27me3 loss. Malignant behavior may be influenced by DNA methyltransferases (DNMT3A). SUFU mutations may carry
Publikováno v:
Neuro-Oncology. 24:vii240-vii240
BACKGROUND Dexamethasone is the primary treatment for tumor-associated edema. Prolonged use can have significant side effects and may negatively impact survival in GBM. Factors associated with steroid dependence and steroid associated side effects (S
Autor:
Peter Pan, Adela Joanta-Gomez, Carlen Yuen, Laura Donovan, Aya Haggiagi, Mary Welch, Fabio Iwamoto, Andrew Lassman
Publikováno v:
Neuro-Oncology. 24:vii202-vii202
INTRODUCTION Time to recurrence is a source of considerable anxiety in glioblastoma. Assuming survival to a certain timepoint without tumor progression, how do odds/outcomes change relative to initial starting conditions? Is there a single timepoint
Autor:
Peter Pan, Marissa Barbaro, Fabio M. Iwamoto, Mary Welch, Carlen Yuen, Aya Haggiagi, Laura Donovan, Andrew B. Lassman, Adela Joanta-Gomez
Publikováno v:
Neuro Oncol
INTRODUCTION Standard of care for glioblastoma consists of surgery, followed by combined chemoradiation and adjuvant chemotherapy, as per the seminal EORTC study from 2005. Clinical trial patients, being a population selected for functional status, h
Publikováno v:
Neuro-oncology Advances
Background Tumor Treating Fields (TTF) have entered clinical practice for newly diagnosed and recurrent glioblastoma (GGM). However, controversies remain unresolved with regard to appropriate usage. We sought to determine TTF usage in major academic
Publikováno v:
Neuro Oncol
BACKGROUND Hyperprogressive disease (HPD), defined as a ≥ 2-fold increase in tumor growth rate (TGR) compared to baseline following initiation of immune checkpoint inhibitors (ICI), has been described in solid tumors but is not well explored high g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7d08f58237779d3501a122653086f9b
https://europepmc.org/articles/PMC6847436/
https://europepmc.org/articles/PMC6847436/
Autor:
Teri Kreisl, Fabio M. Iwamoto, Elizabeth J. Buss, Oscar Padilla, Aya Haggiagi, Angela Lignelli-Dipple, Marissa Barbaro, Laura Donovan, Carl D. Elliston, Tony J. C. Wang, Jeffrey N. Bruce, Adela Joanta-Gomez, Mary Welch, Peter Canoll, Peter Pan, Andrew B. Lassman
Publikováno v:
Neuro Oncol
BACKGROUND Late-delayed radiation effects appear 6 months to years following radiotherapy. We characterize a species of small enhancing lesions in the late-delayed phase of post-radiotherapy that are distinct from the classic descriptions of radiatio
Autor:
Andrew B. Lassman, Aya Haggiagi, Teri Kreisl, Samuel Gedailovich, Jessica Schulte, Mary Welch, Laura Donovan, Adela Joanta-Gomez, Fabio M. Iwamoto
Publikováno v:
Journal of Clinical Oncology. 37:e13575-e13575
e13575 Background: Hyperprogressive disease (HPD) has been described in solid tumor patients treated with immune checkpoint inhibitors (ICI). HPD is defined as a ≥2-fold increase in tumor growth rate (TGR) following initiation of ICI. HPD has not b
Autor:
Teri Kreisl, Andrew B. Lassman, Adela Joanta-Gomez, Mary Welch, Laura Donovan, Fabio M. Iwamoto
Publikováno v:
Neuro-Oncology. 20:vi215-vi215
Quality of life is often impaired in patients with high grade gliomas (HGG) and their caregivers. Resilience refers to one’s ability to maintain or improve their emotional wellbeing in the setting of extreme stressors. In patients with chronic illn
Autor:
Donovan, Laura, Joanta-Gomez, Adela, Kreisl, Teri, Lassman, Andrew B., Welch, Mary, Iwamoto, Fabio
Publikováno v:
Neuro-Oncology; 2018 Supplement, Vol. 20, pvi215-vi215, 1p